Biodesix Inc BDSX
We take great care to ensure that the data presented and summarized in this overview for BIODESIX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BDSX
View all-
Birchview Capital, LP Burlington, VT5.19MShares$7.43 Million6.38% of portfolio
-
Aigh Capital Management LLC Baltimore, MD3.32MShares$4.75 Million1.91% of portfolio
-
Telemark Asset Management, LLC Boston, MA1.33MShares$1.9 Million0.22% of portfolio
-
Essex Investment Management CO LLC Boston, MA926KShares$1.32 Million0.27% of portfolio
-
Wells Fargo & Company San Francisco, CA893KShares$1.28 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA808KShares$1.16 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA535KShares$764,5590.19% of portfolio
-
Black Rock Inc. New York, NY403KShares$576,1580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA385KShares$550,7570.0% of portfolio
-
Legato Capital Management LLC334KShares$478,0630.06% of portfolio
Latest Institutional Activity in BDSX
Top Purchases
Top Sells
About BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Insider Transactions at BDSX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 23
2024
|
Gary Anthony Pestano Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
880
+0.7%
|
-
|
May 23
2024
|
Jack W Schuler |
BUY
Exercise of conversion of derivative security
|
Indirect |
86,960
+0.28%
|
-
|
May 23
2024
|
Matthew Strobeck |
BUY
Exercise of conversion of derivative security
|
Indirect |
347,840
+24.08%
|
-
|
May 23
2024
|
Chris Vazquez Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
880
+7.54%
|
-
|
May 23
2024
|
John Patience |
BUY
Exercise of conversion of derivative security
|
Indirect |
217,400
+4.31%
|
-
|
May 23
2024
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,080
+6.47%
|
-
|
May 23
2024
|
Scott Hutton President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,120
+4.87%
|
-
|
May 23
2024
|
Lawrence T. Kennedy Jr |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,347,840
+30.43%
|
-
|
May 23
2024
|
Kieran O'Kane Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,080
+12.86%
|
-
|
May 21
2024
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,209
+2.34%
|
$0
$0.42 P/Share
|
May 09
2024
|
Kieran O'Kane Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
468
-0.62%
|
$468
$1.48 P/Share
|
May 09
2024
|
Gary Anthony Pestano Chief Development Officer |
SELL
Open market or private sale
|
Direct |
434
-0.35%
|
$434
$1.48 P/Share
|
May 09
2024
|
Chris Vazquez Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
244
-2.4%
|
$244
$1.48 P/Share
|
May 09
2024
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
SELL
Open market or private sale
|
Direct |
980
-0.57%
|
$980
$1.48 P/Share
|
May 09
2024
|
Scott Hutton President & CEO |
SELL
Open market or private sale
|
Direct |
3,764
-0.77%
|
$3,764
$1.48 P/Share
|
May 08
2024
|
Kieran O'Kane Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,489
+1.92%
|
-
|
May 08
2024
|
Gary Anthony Pestano Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,378
+1.09%
|
-
|
May 08
2024
|
Chris Vazquez Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
601
+5.59%
|
-
|
May 08
2024
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,157
+1.8%
|
-
|
May 08
2024
|
Scott Hutton President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,212
+2.44%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 16.7M shares |
---|---|
Exercise of conversion of derivative security | 5.62M shares |
Open market or private purchase | 128K shares |
Open market or private sale | 141K shares |
---|